1.. Introduction
================

The phthalazine derivative azelastine (**A**, [Figure 1](#f1-pharmaceuticals-04-01158){ref-type="fig"}) is an antihistamine used in the treatment of allergic rhinitis \[[@b1-pharmaceuticals-04-01158]\]. Newer agents are more selective inhibitors of the cGMP-inhibited phosphor diesterase (PDE) and casn be exemplified by phthalazine derivatives like MY5445 (**B**, [Figure 1](#f1-pharmaceuticals-04-01158){ref-type="fig"}) \[[@b2-pharmaceuticals-04-01158]-[@b5-pharmaceuticals-04-01158]\]. Zopolrestat (**C**, [Figure 1](#f1-pharmaceuticals-04-01158){ref-type="fig"}) is a phthalazinone derivative that has been in clinical trials; it inhibits aldose reductase and has potential use in the prevention of retinopathy, neuropathy, and cataract formation in diabetes \[[@b6-pharmaceuticals-04-01158]\]. The chemiluminescence reactions of luminol (**D**, [Figure 1](#f1-pharmaceuticals-04-01158){ref-type="fig"}) and related phthalazines have found analytical applications, particularly in biological systems where the inherent signal strength and low signal noise ratio contribute to sensitivity. The hydrogen peroxide/luminol system has been used for the on-line determination by chemiluminescence of nitric oxide in isolated organ perfusates \[[@b7-pharmaceuticals-04-01158]-[@b10-pharmaceuticals-04-01158]\].

Phthalazine derivatives have been widely applied as therapeutic agents due to their anticonvulsant, cardiotonic, vasorelaxant and anti-inflammatory properties \[[@b11-pharmaceuticals-04-01158]-[@b17-pharmaceuticals-04-01158]\] in addition to having antimicrobial activity \[[@b18-pharmaceuticals-04-01158]\].

2.. Results and Discussion
==========================

4-Benzyl-2*H*-phthalazin-1-one (**1**) \[[@b19-pharmaceuticals-04-01158]\] was used as a starting material for this investigation. Reaction of compound **1** with formalin in ethanol afforded 4-benzyl-2-hydroxymethyl-2*H*-phthalazin-1-one (**2**). Treatment of **2** with thionyl chloride afforded the corresponding 4-benzyl-2-chloromethyl-2*H*-phthalazin-1-one (**3**). Interaction of **3** with alcoholic potassium thiocyanate yield the corresponding 4-benzyl-2-thiocyanatomethyl-2*H*-phthalazin-1-one (**4**), while with ethanolic thiourea it afforded 4-benzyl-2-mercaptomethyl-2*H*-phthalazin-1-one (**5**). Treatment of **1** with ethyl chloroacetate in the presence of anhydrous K~2~CO~3~ afforded the corresponding ethyl (2-(4-benzyl-1-oxo-1*H*-phthalazin-2-yl)acetate (**6**). Reaction of **6** with hydrazine hydrate gave the corresponding (4-benzyl-1-oxo-1*H*-phthalazin-2-yl)acetic acid hydrazide (**7**) which was reacted with *p*-tolualdehyde to give the corresponding (4-benzyl-1-oxo-1*H*-phthalazin-2-yl) acetic acid (4-methylbenzylidene) hydrazide (**8**) ([Scheme 1](#f2-pharmaceuticals-04-01158){ref-type="fig"}).

4-Benzyl-1-chlorophthalazine (**9**) \[[@b19-pharmaceuticals-04-01158]\] was used as starting martial from preparation of new 1,4-disubstuted phthalazine derivatives. Thus, interaction of **9** with equimolar amount of aminophenols, aminoacetophenones and *p*-aminobenzoic acid gave the corresponding 4-benzylphthalazin-1-ylamino derivatives (**10a-f**). Compound **9** also reacted with *N*-(4-aminophenyl)acetanilide under reflux to give the corresponding 4-(4-benzylphthalazin-1-ylamino)acetanilide (**10g**), in the case of *p*-phenylene-diamine and/or benzidine but in the case of *p*-aminodiphenyl amine the only isolable product is 4-(4-benzylphthalazin-1-ylamino)diphenylamine (**10h**). Treatment of **9** with sulfanilic acid and/or J-acid (2-amino-5-naphthol-7-sulfonic acid) gave the corresponding 4-(4-benzylphthala-zin-1-ylamino)benzenesulfonic acid (**10i**) and/or 7-(4-benzylphthalazin-1-ylamino)-4-hydroxynaphthalene-2-sulfonic acid (**10j**), while **9** with ammonium thiocyanate gave the corresponding 4-benzylphthalazin-1-ylthiocyanate **(11)**. Interaction of **9** with dibasic aromatic amines in a 1:2 ratio under fusion conditions afforded the corresponding *N,N′*-bis(4-benzyl-phthalazin-1-yl)-1,4-phenylenediamine and/or *N,N′*-bis(4-benzylphthalazin-1-yl)biphenyl-4,4′-diamines (**12a**,**b**). Also, **9** was reacted with ethylenediamine in boiling ethanol to give *N,N′*-bis(4-benzylphthalazin-1-yl)ethane-1,2-diamine (**13**), However, interaction of **9** with 2-hydrazino-4-amino-5-cyano-6-arylpyrimidine gave the corresponding pyrimidine-5-carbonitrile derivatives **14a,b** respectively ([Scheme 2](#f3-pharmaceuticals-04-01158){ref-type="fig"}). Interaction of **9** with methyl anthranilate and/or anthranilic acid gave anthracen-7-one derivative **15** as the only isolable product. The formation of **15** was explained by the formation of intermediate \[**E**\] which undergoes intramolecular ring closure to the final product **15** ([Scheme 3](#f4-pharmaceuticals-04-01158){ref-type="fig"}).

Treatment of **9** with *p*-aminohippuric acid in boiling methanol/TEA, gave the corresponding methyl ester derivative **16** was obtained as the only isolable product. The formation of **16** can be explained by the nucleophilic transformation into benzylphthalazin-1-ylamino derivative \[**F**\] as intermediate which undergoes intramolecular cyclization into oxazolone intermediate \[**G**\] then reacted with a molecule of methanol to give the methyl ester derivative **16** as the final product ([Scheme 3](#f4-pharmaceuticals-04-01158){ref-type="fig"}).

Treatment of **16** with (EtO)~3~CH/Ac~2~O under reflux afforded the corresponding ethoxymethylene derivative **17**. Treatment of **16** with aqueous ammonium hydroxide under reflux in dioxane in the presence of triethylamine afforded the corresponding carboxamide derivative **18** respectively ([Scheme 3](#f4-pharmaceuticals-04-01158){ref-type="fig"}).

3.. Experimental
================

3.1.. General
-------------

Melting points were determined on a Stuart melting point apparatus and are uncorrected. IR spectra were recorded in KBr using a FT-IR 5300 spectrometer and Perkin Elmer spectrum RXIFT-IR system (ν, cm^−1^). The ^1^H NMR at (300 MHz) and ^13^C NMR spectra (75 MHz) were recorded in CDCl~3~ or DMSO-*d~6~* on a Varian Mercury VX-300 NMR spectrometer. Chemical shifts (δ) are related to that of the solvent. Mass spectra were measured on a Shimadzu GMMS-QP-1000 EX mass spectrometer at 70 eV. The elemental analyses were performed at the Microanalytical Center, Cairo University. Cairo (Egypt).

*4-Benzyl-2-hydroxymethyl-2H-phthalazin-1-one* (**2**). A mixture of compound **1** (0.23 g, 1.0 mmol) and formaldehyde solution 38% (0.8 mL) in ethanol (30 mL) was refluxed for 3 hours. The solvent was evaporated under vacuum, and then water (25 mL) was added. The solid obtained was filtered off and recrystallized from ethanol. Colourless crystals, 90%, 0.19 g. mp 115-116 °C; IR (ν~max~, cm^−1^): 3334 (OH), 1640 (CO). ^1^H NMR (CDCl~3~): δ~H~ 4.13 (t, *J* = 8.4 Hz, 1H, OH), 4.31 (s, 2H, CH~2~Ph), 5.69 (d, *J* = 8.4 Hz, 2H, CH~2~OH), 7.30 (m, 5H, Ph-H), 7.71 (m, 3H, phthalazinyl-3H), 8.45 (m, 1H, phthalazinyl-1H); the singlet at 4.134 was cancelled by D~2~O. ^13^C NMR (DMSO-d~6~) δ 37.3 (CH~2~), 60.1 (CH~2~OH), 125.7 (C~4~-Ar), 128 (C~5~), 128.3 (C~8~), 128.8 (C~3~-Ar, C~5~-Ar), 129.1 (C~2~-Ar, C~6~-Ar), 130.2 (C~5a~), 130.3 (C~8a~), 131.2 (C~7~), 132.3 (C~6~), 137.2 (C~1~-Ar), 155.1 (C~4~) and 160.1 (CO). MS, *m/z* (%) = 266 (M^+^, 10.25), 235 (100) together with other peaks at 207 (5.74), 178 (20.38), 149 (15.82), 130 (9.19), 91 (12.03), 57 (17.77); Anal. Calcd for C~16~H~14~N~2~O~2~ (266.10): C, 72.16; H, 5.30; N, 10.52%. Found: C, 71.89; H, 5.02; N, 9.96%.

*4-Benzyl-2-chloromethyl-2H-phthalazin-1-one* (**3**). A mixture of compound **2** (0.26 g, 1.0 mmol) and thionyl chloride (5 mL) was refluxed for 1 hour. The solid obtained was filtered off and recrystallized from benzene. Colourless crystals, 87%, 0.12 g. mp 125-127 °C; IR (ν~max~, cm^−1^): 3046 (C-H aromatic), 1662 (CO). MS, *m/z* (%) = 284 (M^+^, 43.4), M+2 (12.7), 249 (100) together with other peaks at 220 (34.9), 178 (17.9), 130 (29.2), 91 (80.7), 51 (28.9); Anal. Calcd for C1~6~H~13~ClN~2~O (284.07): C, 67.49; H, 4.60; N, 9.84%. Found: C, 66.90; H, 4.08; N, 9.11%.

*4-Benzyl-2-thiocyanatomethyl-2H-phthalazin-1-one* (**4**). A mixture of compound **3** (0.28 g, 1.0 mmol) and potassium thiocyanate (1.0 mmol) in ethanol (30 mL) was refluxed for 3 hours. The solvent was evaporated under vacuum. The solid obtained was filtered off and recrystallized from ethanol. White crystals, 85%, 0.17 g. mp 155-156 °C; IR (ν~max~, cm^−1^): 2158 (SCN), 1664 (CO). MS, *m/z* (%) = 307 (M^+^, 0.7), 249 (56.3), 130 (12.8) and 91 (100); Anal. Calcd for C~17~H~13~N~3~OS (307.36): C, 66.43; H, 4.26; N, 13.67%. Found: C, 66.22; H, 3.98; N, 13.50%.

*4-Benzyl-2-mercaptomethyl-2H-phthalazin-1-one* (**5**). A mixture of compound **3** (0.28 g, 1.0 mmol) and thiourea (1.0 mmol) in ethanol (30 mL) was refluxed for 3 h hours. The solvent was evaporated under vacuum. The solid obtained was filtered off and recrystallized from ethanol. White crystals, 80%, 0.10 g. mp 145-146 °C; IR (ν~max~, cm^−1^): 2750 (SH), 1650 (CO). MS, *m/z* (%) = 282 (M^+^, 17.2), 249 (78.2), 235 (18.1), 132 (27.3), 130 (23.5), 91 (100) 51 (32.8); Anal. Calcd for C~16~H~14~N~2~OS (282.36): C, 68.06; H, 5.00; N, 9.92%. Found: C, 67.45; H, 4.67; N, 9.22%.

*Ethyl (4-benzyl-1-oxo-1H-phthalazin-2-yl)acetate* (**6**). A mixture of compound **1** (0.23 g, 10 mmol) and ethyl chloroacetate (2 mL) and anhydrous K~2~CO~3~ (0.13 g, 1.0 mmol) was refluxed for 4 hours. The solvent was evaporated under vacuum, then water (50 mL) was added. The solid obtained was filtered off and recrystallized from pet. ether and chloroform, respectively. Violet crystals, 65%, 0.13 g. mp 76-78 °C; IR (ν~max~, cm^−1^): 2978 (CH aliphatic), 1744, 1648 (CO). MS, *m/z* (%) = 322 (M^+^, 37.9) and base peak at 248 together with other peak at 249 (97.9), 221 (8.2), 220 (21.5), 219 (24.3), 193 (4.6), 102 (14.6), 91 (98.4), 76 (11.4); Anal. Calcd for C~19~H~18~N~2~O~3~ (322.12): C, 70.79; H, 5.63; N, 8.69%. Found: C, 70.36; H, 5.44; N, 8.52%.

*(4-Benzyl-1-oxo-1H-phthalazin-2-yl)acetic acid hydrazide* (**7**). A mixture of compound **6** (0.32 g, 10 mmol) and hydrazine hydrate (0.8 mL) in ethanol (30 mL) was refluxed for 3 hours. The solvent was evaporated under vacuum, then water (25 mL) was added. The solid obtained was filtered off and recrystallized from ethanol. White crystals, 86%, 0.18 g. mp 130-132 °C; IR (ν~max~, cm^−1^): 3326 (NH), 1684 (CO, carboxylic acid hydrazide), 1642 (CO, phthalazinyl). ^1^H NMR (CDCl~3~): δ~H~ 14.29 (s, 2H, CH~2~Ph), 4.75 (s, 2H, NCH~2~CO), 7.29 (m, 5H, Ar-H), 7.81 (m, 5H, phthalazinyl-3H and NH~2~), 8.25 (m, 1H, phthalazinyl-H) and 9.30 (s, 1H, CONH; cancelled by D~2~O). MS, *m/z* (%) = 308 (M^+^, 0), 278 (7.2), 277 (23.4), 249 (44.9), 130 (15.3), 91 (100); Anal. Calcd for C~17~H~16~N~4~O (308.33): C, 66.22; H, 5.23; N, 18.17%. Found: C, 66.09; H, 5.12; N, 17.89%.

3.2.. General Procedure for the Synthesis of Benzylphthalazin-1-ylamino Derivatives **10a-h**
---------------------------------------------------------------------------------------------

A mixture of compound **9** (0.25g, 10 mmol) and aromatic amine (10 mmol) in ethanol (30 mL) was refluxed for 3 hours. The solvent was evaporated under vacuum. The solid obtained was filtered off to give crude products

*(4-Benzylphthalazin-1-ylamino)phenols (10a,b)*. Compound **10a** Yellow crystals, 90%, 0.17 g. mp 240-242 °C; IR (ν~max~, cm^−1^): 3258 (NH and OH phenolic) as broad peak. MS, *m/z* (%) = 307 327 (M^+^, 42.2) and the base peak at 326 together with other peaks at 325 (84.3), 91 (62.6); Anal. Calcd for C~21~H~17~N~3~O (327.10): C, 77.04; H, 5.23; N, 12.84%. Found: C, 76.83; H, 5.02; N, 12.56%. Compound **10b**: Yellow crystals, 80%, 0.12 g. mp 236-237 °C; IR (ν~max~, cm^−1^): 3268 (NH and OH phenolic) as broad peak. MS, *m/z* (%) = 327 (M^+^, 40.0) and the base peak at 326 together with other peaks at 325 (86.7), 91 (50.8); Anal. Calcd for C~21~H~17~N~3~O (327.10): C, 77.04; H, 5.23; N, 12.84%. Found: C, 76.75; H, 5.01; N, 12.59%.

*7-(4-Benzylphthalazin-1-ylamino)naphthalen-2-ol* (**10c**). Green crystals, 70%, 0.09 g. mp 242-243 °C; IR (ν~max~, cm^−1^): 3272 (OH and NH) as broad peak. ^1^H NMR (DMSO-*d~6~*): δ~H~ 24.65 (s, 2H, CH~2~Ph), 7.08-7.33, 7.55-7.58, 8.09-8.11 (ms, 9H, Ar-H), 7.38 (d, *J* = 7.8 Hz, 1H, Ar-H), 7.78 (d, *J* = 9 Hz, 1H, Ar-H), 7.86 (d, *J* = 9 Hz, 1H, Ar-H), 8.14 (d, *J* = 1.8 Hz, 1H, Ar-H), 8.16 (s, 1H, NH, exchangeable with D~2~O), 8.33 (d, *J* = 1.8 Hz, 1H, Ar-H), 9.04 (d, *J* = 7.8 Hz, 1H, Ar-H) and 9.96 (s, 1H, phenolic-OH, exchangeable with D~2~O).; Anal. Calcd for C~25~H~19~N~3~O (377.13): C, 79.55; H, 5.07; N, 11.13%. Found: C, 79.32; H, 4.87; N, 10.92%.

*1-\[(4-Benzylphth-alazin-1-ylamino)phenyl\]ethanones* (**10d,e**). Compound **10d**: White crystals, 75%, 0.11 g. mp 225-226 °C; IR (ν~max~, cm^−1^): 3390 (NH), 1662 (CO). MS, *m/z* (%) = 353 (73.56) and the base peak at 352 together with other peaks at 311 (3.7), 310 (11.97), 262 (10.56), 220 (5.37), 219 (4.82) and 91 (54.14); Anal. Calcd for C~23~H~19~N~3~O (353.05): C, 78.16; H, 5.42; N, 11.89%. Found: C, 77.88; H, 5.23; N, 11.64%. Compound **10e**: Yellow crystals, 80%, 0.13 g. mp 260-261 °C; IR (ν~max~, cm^−1^): 3312 (NH), 1670 (CO). ^1^H NMR (DMSO-*d~6~*): δ~H~ 2.57 (s, 3H, CH~3~CO), 4.75 (s, 2H, CH~2~Ph), 7.21-7.27 (m, 2H, Ar-H), 7.31 and 7.40 (AB-q, *J* = 7.2 Hz, 4H, Ar-H), 8.01 (s, 1H, NH), 8.10-8.18 (m, 5H, Ar-H) and 8.39, 8.94 (2d, *J* = 7.8 Hz, 2H, Ar-H); Anal. Calcd for C~23~H~19~N~3~O (353.23): C, 78.18; H, 5.42; N, 11.89%. Found: C, 77.97; H, 5.18; N, 11.69%.

*4-(4-Benzylphthalazin-1-ylamino)benzoic acid* (**10f**). Yellow crystals, 85%, 0.16 g. mp 280-281 °C; IR (ν~max~, cm^−1^): 3224 (NH and OH), 1676 (CO). MS, *m/z* (%) = 355 (38.4) and base peak at 354 together with other peaks at 310 (3), 234 (5.3), 204 (9.9), 219 (6.9), 204 (9.9), 178 (10.1), 102 (15.9), 91 (68.3), 90 (60.2), 77 (30.6) and 76 (29.7); Anal. Calcd for C~22~H~17~N~3~O~2~ (355.16): C, 74.35; H, 4.82; N, 11.82%. Found: C, 74.14; H, 4.57; N, 11.60%.

*4-(4-Benzylphthalazin-1-ylamino)diphenyl amine* (**10g**). Green crystals, 70%, 0.13 g. mp 215-217 °C; IR (ν~max~, cm^−1^): 3276 (NH). MS, *m/z* (%) = 402 (M^+^, 46.5), 117 (88.7), 92 (60.32), 76 (28.37), 91 (18.88), 57 (87.49), 56 (29.88) & 55 (100); Anal. Calcd for C~27~H~22~N~4~ (402.02): C, 80.57; H, 5.51; N, 13.92%. Found: C, 80.44; H, 5.49; N, 13.75%.

*4-(4-benzylphthalazin-1-ylamino)acetanilide* (**10h**). Yellow crystals, 80%, 0.18 g. mp \> 340 °C; IR (ν~max~, cm^−1^): 3428 (NH), 1620 (CO). MS, *m/z* (%) = 368 (M^+^, 12.94), 235 (10.25), 149 (88.35), 117 (78.7), 92 (63.32), 76 (28.37), 91 (18.88), 57 (87.49), 56 (29.88) and 55 (100); Anal. Calcd for C~23~H~20~N~4~O (368.17): C, 74.98; H, 5.47; N, 15.21%. Found: C, 74.80; H, 5.32; N, 15.12%.

3.3.. General Method for the Synthesis of Sulfonic Acid Derivatives **10i, j**
------------------------------------------------------------------------------

A mixture of compound **9** (0.25 g, 1.0 mmol) in ethanol (30 mL) sulfanilic acid or (2-amino-5-naphthol-7-sulfonic acid) (1.0 mmol) and 2 drops of triethylamine (TEA) was refluxed for 3 hours. The solvent was evaporated under vacuum. The solid obtained was filtered off and recrystallized from dioxane.

*4-(4-Benzylphthalazin-1-ylamno)benzenesulfonic acid* (**10i**). Yellow crystals, 80%, 0.17 g. mp \> 340 °C; IR (ν~max~, cm^−1^): 3402 (OH), 3256 (NH). MS, *m/z* (%) = 391 (M^+^, 4.7), 327 (18.12), 311 (72.15), 310 (95.64), 235 (40.60), 219 (89.60), 193 (100), 92 (57.72) and 91 (16.78). Anal. Calcd for C~21~H~17~N~3~O~3~S (391.09): C, 64.43; H, 4.38; N, 10.73%. Found: C, 64.36; H, 4.28; N, 10.65%.

*7-(4-benzylphthalazin-1-ylamino)-4-hydroxynaphthalene-2-sulfonic acid* (**10j**). Yellow crystals, 65%, 0.13 g. mp \> 340 °C; IR (ν~max~, cm^−1^): 3308 (OH), 3066 (NH). MS, *m/z* (%) = 457 (M^+^, 5.3), 455 (naphthsaltone cationic radical, 59.1), 222 (5.1), 235 (100), 203 (6.4), 193 (3.6) and 178 (15.8); Anal. Calcd for C~25~H~19~N~3~O~4~S (457): C, 65.63; H, 4.19; N, 9.18%. Found: C, 65.54; H, 3.97; N, 9.10%.

*Synthesis of N,N′-bis(4-benzylphthalazin-1-yl)-1,4-phenylenediamine* (**11**) *and N,N′-bis(4-benzylphthalazin-1-yl)biphenyl-4,4′-diamine* (**12**). A mixture of compound **9** (0.50 g, 20 mmol) and dibasic aromatic amines (10 mmol) in ethanol (30 mL) was refluxed for 3 hours. The solvent was evaporated under vacuum. The solid obtained was filtered off and recrystallized from dioxane. Compound **11** Yellow crystals, 70%, 0.13 g. mp 250-251 °C; IR (ν~max~, cm^−1^): 3344 (NH). MS, *m/z* (%) = 544 (M^+^, 0.74) and base peak at 325 together with other peaks at 234 (5.7), 219 (3.29), 106 (1.74), 91 (13.66), 76 (1.25); Anal. Calcd for C~36~H~28~N~6~ (544.27): C, 79.39; H, 5.18; N, 15.43%. Found: C, 79.08; H, 5.06; N, 15.22%. Compound **12**: Yellow crystals, 70%, 0.12 g. mp \> 340 °C; IR (ν~max~, cm^−1^): 3277 (NH). MS, *m/z* (%) = 620 (M^+^, O), M/2 (310, 9.3); the base peak at 401 and other peaks at 102 (1.8), 91 (17.1); Anal. Calcd for C~42~H~32~N~6~ (620.13): C, 81.27; H, 5.20; N, 13.54%. Found: C, 80.96; H, 5.04; N, 13.30%.

*N,N′-bis(4-benylphthalazin-1-yl)ethane-1,2-diamine* (**13**). A mixture of compound **9** (0.50 g, 20 mmol) and ethylenediamine (10 mmol) in absolute ethanol (30 mL) anhydrous K~2~CO~3~ was refluxed for 4 hours. The obtained was cooled to room temperature, then diluted with water. The solid obtained was filtered off and recrystallized from ethanol. White crystals, 60%, 0.21 g. mp 234-235 °C; IR (ν~max~, cm^−1^): 3316, 3260 (NH) 2930, 2870 (C-H aliphatic). ^1^H NMR (DMSO-*d~6~*): δ~H~ 3.93 (s, 4H, CH~2~-CH~2~), 4.48 (s, 4H, 2CH~2~Ph), 7.14-7.32 (m, 10H, Ar-H), 7.78-7.28 (m, 4H, Ar-H), 7.93-7.90 (br s, 2H, NH; exchangeable with D~2~O), 8.00-8.021(m, 2H, Ar-H) and 8.26-8.29 (m, 2H, Ar-H); Anal. Calcd for C~32~H~28~N~6~ (496.60): C, 77.39; H, 5.68; N, 16.92%. Found: C, 76.29; H, 5.45; N, 16.65%.

3.4.. General Method for the Synthesis of Hydrazino Pyrimidine Derivatives **14a,b**
------------------------------------------------------------------------------------

A mixture of compound **9** (0.25 g, 10 mmol) and 2-hydrazino-4-amino-5-cyano-6-arylpyrimidine (10 mmol) in *n*-butanol (30 mL) was refluxed for 3 hours. The solvent was evaporated under vacuum. The solid obtained was filtered off and recrystallized from dioxane.

*4-Amino-2-\[N′-(4-benzylphthalazin-1-yl)hydrazino\]-6-(4-methoxyphenyl)-pyrimidine-5-carbonitrile* (**14a**). White crystals, 75%, 0.16 g. mp 294-295 °C; IR (ν~max~, cm^−1^): 3450, 3210 (NH), 2206 (CN), 1634 (C=N). ^1^H NMR (DMSO-*d~6~*): δ~H~ 3.84 (s, 3H, OCH~3~), 4.58 (s, 2H, CH~2~Ph), 7.10 and 7.13 (2d, *J* = 8.4 Hz), 2H, Ar-H), 7.17 and 7.22 (2d, *J* = 7.8 Hz, 2H, Ar-H), 7.37 and 7.57 (2d, *J* = 7.8 Hz, 4H, Ar-H), 8.18 and 8.46 (2d, *J* = 8.1 Hz, 2H, Ar-H), 8.684 (s, 1H, Ar-H), 6.99 and 7.88 (m, 2H, Ar-H), 6.250 (br s, 2H, NH~2~), 8.90 (br s, 2H, 2-NH); Anal. Calcd for C~27~H~22~N~8~ (474.02): C, 68.34; H, 4.67; N, 23.612%. Found: C, 68.34; H, 4.55; N, 23.54%.

*4-Amino-2-\[N′-(4-benzylphthalazin-1-yl)hydrazino\]-6-(4-chorophenyl)pyramidine-5-carbonitrile* (**14b**). White crystals, 80%, 0.19 g. mp 274-275 °C; IR (ν~max~, cm^−1^): 3380, 3270 (NH), 2192 (CN), 1638 (C=N). MS, *m/z* (%) = 478 (M^+^, and M+2), 462 (19.22), 368 (14.61), 236 (12.68), 275 (75.31), 138 (36.35), 128 (46.12), 111 (29.49), 91(100); Anal. Calcd for C~26~H~19~ClN~8~ (478.01): C, 65.20; H, 4.00; N, 23.40%. Found: C, 65.08; H, 3.87; N, 23.29%.

*5-Benzyl-6,6a,12-triazobenzo\[a\]anthracen-7-one* (**15**). A mixture of compound **9** (0.25 g, 10 mmol) and methyl anthranilate or anthranilic acid (10 mmol) in absolute ethanol (30 mL) and 2 drops of triethylamine (TEA) was refluxed for 3 hours. The solvent was evaporated under vacuum. The solid obtained was filtered off and recrystallized from dioxane. Yellow crystals, 80%, 0.16 g. mp 176-178 °C; IR (ν~max~, cm^−1^): 1704 (CO); MS, *m/z* (%) = 337 (M^+^, 66.92), 336 (100) and 91 (13.09); Anal. Calcd for C~22~H~15~N~3~O (337.12): C, 78.32; H, 4.48; N, 12.46%. Found: C, 78.19; H, 4.37; N, 12.30%.

*\[4-(4-Benzylphthalazin-1-ylamino)benzoylamino\]acetic acid methyl ester* (**16**). A mixture of compound **9** (0.25 g, 10 mmol) and *p*-aminohippuric acid (10 mmol) in methanol (30 mL) and three drops of TEA was refluxed for 3 hours. The solvent was evaporated under vacuum. The solid obtained was filtered off and recrystallized from dioxane. Yellow crystals, 90%, 0.18 g. mp 165-167 °C; IR (ν~max~, cm^−1^): 3110, 3328 (NH), 1752 (CO), 1642 (CONH). ^1^H NMR (DMSO-*d~6~*): δ~H~ 3.67 (s, 3H, OCH~3~), 3.95 (d, *J* = 5.4 Hz), 1H, non equivalent CH~2~ protons), 4.04 (d, *J* = 5.4 Hz), 1H, non equivalent CH~2~ protons), 4.73 (s, 2H, PhCH~2~), 7.88 and 8.006 (2d, *J* = 8.7 Hz, 2H, Ar-H), 8.44 (d, *J* = 7.8 Hz, 1H, Ar-H), three sets of multipletes at (7.24-7.30), (8.14-8.28), (8.93-9.01) (6H, Ar-H and NH), 7.33 and 7.41 (AB-q, *J* = 7.2Hz, 4H, Ar-H), 10.80 (hump, 1H, NH, exchangeable by D~2~O).; MS, *m/z* (%) = 426 (M^+^, 48.2), 425 (100), 338 (27.8), 310 (5.4), 219 (2.7), 128 (5.4) and 91 (37.2).; Anal. Calcd for C~15~H~22~N~4~O~3~ (426.46): C, 70.41; H, 5.20; N, 13.14%. Found: C, 70.25; H, 5.07; N, 12.87%.

*Methyl 2-(4-(4-benzylphthalazin-1-ylamino)benzamido)-3-ethoxyacrolate* (**17**). A mixture of compound **16** (0.42 g, 1.0 mmol) and triethyl orthoformate (0.14 g, 1.0 mmol) in acetic anhydride (10 mL) was refluxed for 5 hours, and then allowed to cool at room temperature and diluted with water (20 mL). The solid obtained was filtered off and recrystallized from dioxane Yellow crystals, 60%, 0.17 g. mp 175-177 °C; IR (ν~max~, cm^−1^): 3060 (C-H olefinic) 3366 (NH), 2942 (C-H aliphatic), 1752, 1666 (CO). ^1^H NMR (DMSO-*d~6~*): δ~H~ 2.08 (t, 3H, CH~2~CH~3~), 3.64 (s, 3H, COOCH~3~), 4.01 (q, 2H, CH~2~CH~3~), 4.75 (s, 2H, CH~2~Ph), (7.17-8.38) (sets of multiplets, 15H, Ar-H and 2NH), 8.97 (s, 1H, =CH); Anal. Calcd for C~28~H~26~N~4~O~4~ (482.52): C, 69.70; H, 5.43 N, 11.49%. Found: C, 69.63; H, 5.23; N, 11.49%.

*2-(4-(4-Benzylphthalazin-1-ylamino)benzamido)acetamide* (**18**). To compound **16** (0.42 g, 1.0 mmol) and distilled water and/or ammonium hydroxide, two drops of triethylamine (TEA) were added, and the mixture was refluxed in dioxane (15 mL) for 2 hours. The solvent was evaporated under vacuum. The solid obtained was filtered off and recrystallized from dioxane. Yellow crystals, 75%, 0.19 g. mp 240-242 °C; IR (ν~max~, cm^−1^): 3272, 3354(NH), 1734, 1640 (CO); MS, *m/z* (%) = 411 (55.9), 394 (20.7), 355 (59), 354 (100), 338 (48.0), 246 (32.8); Anal. Calcd for C~24~H~21~N~5~O~2~ (411): C, 70.06; H, 5.14; N, 17.02%. Found: C, 69.89; H, 5.07; N, 16.93%.

3.5.. Antibacterial Activity
----------------------------

The newly synthesized compounds were screened for their antimicrobial activities *in vitro* against two species of Gram-negative bacteria *Pseudomonas aeruginosa* (MTCC 741); *Escherichia coli* (NCTC-10410); and four Gram-positive bacteria, *Bacillus cereus* (ATGG 14579); *Bacillus subtilis* (MTCC 441); *Bacillus sphaericus* (MTCC 11); *Staphylococcus* (MTCC 96); and two fungus, *Aspergillus ochraceus Wilhelm* (AUCC-230); *Penicillium chrysogenum Thom* (AUCC-530). The activities of these compounds were tested using the disc diffusion method \[[@b20-pharmaceuticals-04-01158]\]. For bacteria and the paper disk diffusion method \[[@b21-pharmaceuticals-04-01158]\] for fungi. The area of zone of inhibition was measured using Ampicillin; tetracycline and norfloxacin (30 μg mL^−1^) as standard antibiotic and mycostatin (30 μg mL^−1^) was used as a reference antifungal. The tested compounds were dissolved in *N,N*-dimethylformamide (DMF) to give a solution of 1 mg mL^−1^. The inhibition zones were measured in millimeters at the end of an incubation period of 48 hours at 28 °C. *N,N*-dimethylformamide (DMF) showed no inhibition zone. Test results are shown in [Table 1](#t1-pharmaceuticals-04-01158){ref-type="table"}

3.6.. Antibacterial Activities
------------------------------

The screening results indicate that compounds **2--8** and **11** show weaker inhibitory activity than the standard drugs, while compounds **15--18** are moderately inhibitory, compared to the standard drugs. Compounds **10a--j**, **12**, **13 and 14a,b** showed nearly the same inhibition activity asn antibacterial activity ([Table 1](#t1-pharmaceuticals-04-01158){ref-type="table"}). It clear that decomposition of chloride atom at C-1 of 4-benzyl-1-chlorophthalazine with N-nucleophiles is responsible for the antimicrobial activities.

4.. Conclusions
===============

The results from this screening demonstrated that replacement of the hydrogen atom attached to the phthalazine nucleus at N-1 with amino derivatives (compounds **10a-j**), diimino derivatives (compounds **12a,b-13**) and pyrimidine derivatives (**14a,b**) resulted in spectrum if moderate antibacterial activity against all tested Gram positive and Gram negative fungi.

![Phthalazine derivatives (azelastin, MY 5445, zopolrestat and luminol).](pharmaceuticals-04-01158f1){#f1-pharmaceuticals-04-01158}

![Synthesis of phthalazine-1-one derivatives.](pharmaceuticals-04-01158f2){#f2-pharmaceuticals-04-01158}

![Reactions of 4-benzyl-1-chlorophthalazine with amines derivatives.](pharmaceuticals-04-01158f3){#f3-pharmaceuticals-04-01158}

![Synthesis of triazobenzobenzo\[a\]anthrcen-7-one, methyl ester and carboxamide derivatives.](pharmaceuticals-04-01158f4){#f4-pharmaceuticals-04-01158}

###### 

Antimicrobial activity of the new compounds.

  **Compd. No. [a](#tfn1-pharmaceuticals-04-01158){ref-type="table-fn"}**   **Inhibition zone diameter in mm**                                 
  ------------------------------------------------------------------------- ------------------------------------ ---- ---- ---- ---- ---- ---- ----
  **1**                                                                     10                                   12   10   14   12   10   11   13
  **2**                                                                     14                                   10   12   11   10   13   10   11
  **3**                                                                     10                                   10   14   12   11   10   14   10
  **4**                                                                     13                                   10   12   13   10   12   10   12
  **5**                                                                     11                                   14   10   13   14   13   12   13
  **6**                                                                     14                                   10   13   10   12   14   11   14
  **7**                                                                     10                                   12   15   12   10   11   10   11
  **8**                                                                     12                                   13   10   14   10   14   10   10
  **10a**                                                                   16                                   15   14   15   15   16   17   15
  **10b**                                                                   18                                   19   18   17   15   19   14   17
  **10c**                                                                   16                                   16   19   15   18   14   17   18
  **10d**                                                                   15                                   17   16   19   17   15   16   14
  **10e**                                                                   17                                   16   14   17   19   16   19   19
  **10f**                                                                   16                                   15   17   18   17   14   15   17
  **10g**                                                                   18                                   15   15   16   16   17   18   16
  **10h**                                                                   19                                   18   14   15   17   15   14   19
  **10i**                                                                   17                                   16   17   19   18   15   17   15
  **10j**                                                                   18                                   15   19   16   18   15   16   14
  **11**                                                                    12                                   10   14   12   10   14   10   11
  **12a**                                                                   20                                   22   20   19   20   22   20   20
  **12b**                                                                   20                                   23   22   24   24   20   20   20
  **13**                                                                    22                                   20   23   22   23   20   24   22
  **14a**                                                                   23                                   22   24   23   22   24   23   23
  **14b**                                                                   24                                   20   20   20   22   24   20   22
  **15**                                                                    19                                   22   23   22   24   20   20   21
  **16**                                                                    18                                   17   18   17   19   18   16   17
  **17**                                                                    17                                   19   16   19   17   19   15   16
  **18**                                                                    15                                   18   15   17   18   16   18   15
  **Ampicillin**                                                            22                                   22   22   22   22   22   \-   \-
  **Tetracycline**                                                          20                                   20   20   20   20   20   \-   \-
  **Norfloxacin**                                                           25                                   25   25   25   25   25   \-   \-
  **Mycostatin**                                                            \-                                   \-   \-   \-   \-   \-   20   20

*c* = 1 mg mL^−1^ of new compounds in DMF. Microorganisms: *Pseudomonas aeruginosa* (MTCC 741); *Escherichia coli* (NCTC-10410); *Bacillus cereus* (ATGG 14579); *Bacillus subtilis* (MTCC 441); *Bacillus sphaericus* (MTCC 11); *Staphylococcus* (MTCC 96); *Aspergillus ochraceus Wilhelm* (AUCC-230); *Penicillium chrysogenum Thom* (AUCC-530).
